Search Results
Mar 12, 2026, 08:00 ET Pomelo Care Publishes Peer-Reviewed Research Linking Virtual Maternity Care to Improved Outcomes and Reduced NICU Utilization
eonard Davis Institute of Health Economics at the University of Pennsylvania (Penn LDI), presented at the
More news about: Pomelo Care
Mar 09, 2026, 08:00 ET Relativity Reinforces Its Role in Legal Data Intelligence with Brand Refresh at Legalweek 2026
decisively to the cloud, and today it is bringing that same foresight to support the mounting demands of modern legal work. Legal Data Intelligence (LDI) spans litigation, investigations, regulatory inquiries, data breach responses, privacy matters, contract reviews, public records requests, data subject
More news about: Relativity
Mar 09, 2026, 08:00 ET Relativity Reinforces Its Role in Legal Data Intelligence with Brand Refresh at Legalweek 2026
decisively to the cloud, and today it is bringing that same foresight to support the mounting demands of modern legal work. Legal Data Intelligence (LDI) spans litigation, investigations, regulatory inquiries, data breach responses, privacy matters, contract reviews, public records requests, data subject
More news about: Relativity
Dec 02, 2025, 20:00 ET Mod Scenes and Modular Backdrops Announce Strategic Partnership to Expand Event Production Capabilities in United States
with their existing inventory. Now, event producers can get it directly through Mod Scenes. The partnership will be officially launched at the LDI (Live Design International) trade show in Las Vegas during the New Technologies Breakfast on December 7, 2025. Attendees are invited to visit the Mod
More news about: Modular Backdrops
Nov 24, 2025, 13:57 ET University of Phoenix leaders present at PACRAO Annual Conference event focused on advancing knowledge of professionals engaged in enrollment and academic services
PACRAO's Leadership Development Institute (LDI), with McQuarie serving as faculty and Ghiorzi as associate faculty. The LDI provides professional growth opportunities for emerging leaders in admissions, records and registration. The program
More news about: University of Phoenix
Nov 14, 2025, 08:05 ET Office Technology Industry's Frank Award Winners Revealed
Report's Annual Dealer Survey and reflect the opinions of office technology dealers nationwide. Jerry Blaine, president and CEO, and co-founder of LDI Connect, was presented with the Frank G. Cannata Philanthropy Award, named in honor of the founder of The Cannata Report. Stew Campbell of Datamax
More news about: The Cannata Report
Nov 04, 2025, 07:00 ET Broadridge Reports First Quarter Fiscal 2026 Results
iJoin In September 2025, the Company acquired LDI-MAP, LLC ("iJoin"), a retirement plan technology provider specializing in participant onboarding, engagement, and analytics solutions for the retirement
More news about: Broadridge Financial Solutions, Inc.
Oct 25, 2025, 11:00 ET BIMZELX® (bimekizumab-bkzx) Three-Year Rheumatology Data at ACR 2025 Demonstrated Sustained Inflammation Control in Psoriatic Arthritis and Axial Spondyloarthritis
Complete resolution of dactylitis, LDI=0 (NRI), in patients with dactylitis at baseline (LDI >0; BE OPTIMAL: n=89;
More news about: UCB
Aug 05, 2025, 16:01 ET AMGEN REPORTS SECOND QUARTER 2025 FINANCIAL RESULTS
details from Part 1 of the Phase 2 study of MariTide and complete results from the primary analysis of the Phase 1 pharmacokinetics low dose initiation (PK-LDI) study evaluating lower starting doses of MariTide were presented at the American Diabetes Association 85th Scientific Sessions and simultaneously
More news about: Amgen
Jun 23, 2025, 14:31 ET RESULTS FROM AMGEN'S PHASE 2 OBESITY STUDY OF MONTHLY MARITIDE PRESENTED AT THE AMERICAN DIABETES ASSOCIATION 85TH SCIENTIFIC SESSIONS
conservatively defined treatment estimand used in the Phase 2 study. About Phase 1 PK-LDI Study (NCT06976372)The Phase 1 pharmacokinetics low dose initiation (PK-LDI) study was a Phase 1, randomized, double-blind, multiple-dose, parallel-group study to investigate the PK,
More news about: Amgen
Jun 18, 2025, 09:00 ET AMGEN'S PHASE 2 MARITIDE DATA TO BE PRESENTED AT THE AMERICAN DIABETES ASSOCIATION 85TH SCIENTIFIC SESSIONS
and tolerability data from Part 1 of the Phase 2 study, complete data from the primary analysis of the Phase 1 pharmacokinetics low dose initiation (PK-LDI) study, and additional information on the Phase 3 MARITIME Chronic Weight Management studies. Topline results from Part 1 of the Phase 2 study were
More news about: Amgen